Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Compared with those assigned to aspirin, patients assigned to a P2Y12 inhibitor had a lower net composite of adverse cardiac and cerebrovascular events. HealthDay News — For patients who undergo ...

NEW ORLEANS — Two new studies from Asia provide more evidence that extended monotherapy with clopidogrel (Plavix, Sanofi) or another P2Y12 inhibitor antiplatelet, rather than either dual antiplatelet ...

Please provide your email address to receive an email when new articles are posted on . P2Y12 monotherapy after PCI was not as protective from ischemic events vs. DAPT with aspirin. Monotherapy did ...

In the study, which entered people with both AF and recent acute coronary syndromes (ACS) or percutaneous coronary intervention (PCI), all of whom went on a P2Y12 inhibitor, such as clopidogrel, the ...

Madrid, Spain – 31 August 2025: Noninferiority was not demonstrated for death and ischaemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after ...

Concept Medical has enrolled the first patients in the STARS DAPT global trial evaluating its polymer-free Abl ...

Patients with atrial fibrillation (AF) who’ve recently experienced an acute coronary syndrome or undergone PCI are best served by an antithrombotic strategy that includes a P2Y12 inhibitor and a ...

NEW ORLEANS, LA—A single subcutaneous injection of a novel, small-molecule glycoprotein IIb/IIIa inhibitor administered at first medical contact in patients with suspected STEMI improves the patency ...